drugset / Trial / NCT00219102

A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients

NCT00219102

Phase 3 Completed 336 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the blood pressure lowering effect and safety of aliskiren used in combination with valsartan/hydrochlorothiazide in diabetic patients with essential hypertension, not adequately responsive to the combination of valsartan and hydrochlorothiazide

Timeline

Start
2005-06
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg